000797983 000__ 05574cam\a2200481Mu\4500
000797983 001__ 797983
000797983 005__ 20230306143459.0
000797983 006__ m\\\\\o\\d\\\\\\\\
000797983 007__ cr\cn\nnnunnun
000797983 008__ 170812s2017\\\\sz\\\\\\o\\\\\000\0\eng\d
000797983 019__ $$a1000355568$$a1000594603
000797983 020__ $$a9783319595047$$q(electronic book)
000797983 020__ $$a3319595040$$q(electronic book)
000797983 020__ $$z9783319595030
000797983 020__ $$z3319595032
000797983 035__ $$aSP(OCoLC)on1000451744
000797983 035__ $$aSP(OCoLC)1000451744$$z(OCoLC)1000355568$$z(OCoLC)1000594603
000797983 040__ $$aEBLCP$$beng$$cEBLCP$$dYDX$$dN$T$$dGW5XE$$dDKU$$dOCLCF$$dUAB
000797983 049__ $$aISEA
000797983 050_4 $$aRM151
000797983 08204 $$a615.19
000797983 1001_ $$aTrottet, Lionel.
000797983 24510 $$aDermal drug selection and development :$$ban industrial perspective /$$cLionel Trottet, Howard Miabach.
000797983 260__ $$aCham :$$bSpringer,$$c2017.
000797983 300__ $$a1 online resource (154 pages)
000797983 336__ $$atext$$btxt$$2rdacontent
000797983 337__ $$acomputer$$bc$$2rdamedia
000797983 338__ $$aonline resource$$bcr$$2rdacarrier
000797983 5050_ $$aDedication; Preface; Acknowledgements; Contents; Chapter 1: Introduction; 1.1 Developing a New Medicine; 1.2 Key Risks at the Candidate Selection Stage; 1.3 Attrition in the Pharmaceutical Industry; 1.4 Evolution of the Pharma R&D Over the Last Two Decades; 1.5 Pharma R&D Productivity in Decline; 1.6 Cost of Pharma R&D and Cost Up to Candidate Selection; 1.7 Increased Risks in Developing a Topical Drug; 1.8 Increased Opportunities to Develop a Topical Drug; References; Chapter 2: Choosing Topical Drug Candidate: Historical Overview
000797983 5058_ $$a2.1 The Pragmatic Topical Drug Development Approach: An Existing Oral/Systemic Drug is Further Developed as a Topical2.1.1 Local Anaesthetics (<1900); 2.1.2 Corticosteroids (1952); 2.1.3 Retinoids (1962); 2.1.4 Antifungals (1967); 2.1.5 NSAIDS (1971); 2.1.6 Antivirals (1983); 2.1.7 Vitamin D3 Derivatives (Late 1980s); 2.1.8 Immunosuppressors (1992); 2.1.9 Summary; 2.2 Moving towards Improved Topical Drug Candidate Selection Processes: Use of In Vivo Models; 2.2.1 The Particular Case of Corticosteroids: Use of Human Models (Early 1960s); 2.2.2 Topical Rodent Models (1960s)
000797983 5058_ $$a2.2.3 Combined Use of Topical Models and Systemic Rodent Models (1980s)2.2.4 Use of Topical Pig Models (1990s); 2.3 Historical Topical Drug Candidate Selection Summary; References; Chapter 3: Key Factors Affecting the Efficacy of a Topical Drug Candidate: Learnings from Past Topical Drug Development; 3.1 Skin Barrier Condition vs. "Easiness" of Topical Drug Development; 3.1.1 Skin and Its Barrier; 3.1.2 Skin Disease, Target Site in Skin and Skin Barrier Properties; 3.1.3 Success Rate of First in Class Topical Drugs; 3.1.3.1 Easy Development Drug Class; 3.1.3.2 Difficult Development Drug Class
000797983 5058_ $$a3.1.4 Summary of Impact of Skin Disease, Its Target Site, Its Barrier and Success Rate of Topical Drug Development3.2 Drug Potency and Clinical Efficacy; References; Chapter 4: Topical Versus Oral/Systemic Drug Discovery; 4.1 Drug Discovery Evolution; 4.2 Oral/Systemic Drug Discovery; 4.3 Topical Drug Discovery; 4.4 Two Key Differences in Discharging Risk in Between the Oral/Systemic and Topical Drug Discovery Processes; 4.4.1 Defining Target Tissue (Skin) Concentration; 4.4.2 Checking that Pharmacokinetic Parameters Are Appropriate; 4.4.2.1 Bioavailability and Delivery Rate
000797983 5058_ $$a4.4.2.2 Concept of "Half-Life" in Topical Therapy4.5 Consequences for Preclinical Stage: "Maximising Percutaneous Flux"; 4.6 Learnings from the Oral Drug Development Process; References; Chapter 5: Assessing Drug Concentration in Skin: Direct and Indirect Methods; 5.1 Direct Methods; 5.1.1 Tape Stripping (Vitro/Vivo); 5.1.1.1 Description + Use of Method; 5.1.1.2 Pros; 5.1.1.3 Cons; 5.1.2 Skin Biopsy; 5.1.2.1 Description + Use of Method; 5.1.2.2 Pros; 5.1.2.3 Cons; 5.1.3 In Vitro Percutaneous Studies: Skin Tissue Concentration; 5.1.3.1 Description + Use of Method; 5.1.3.2 Pros; 5.1.3.3 Cons; 5.1.4 Suction Blister.
000797983 506__ $$aAccess limited to authorized users.
000797983 520__ $$aThe authors show how the pharmaceutical industry faces the development of dermal drugs and provide the only book of its kind that describes how the industry develops and selects dermal drugs, complete with the challenges and opportunities of the field. Delivery of drugs through the skin has been an attractive and challenging area for research, and advances in modern technologies have resulted in a larger number of drugs being delivered transdermally, including conventional hydrophobic small molecule drugs, hydrophilic drugs and macromolecules. Offering the perspective from the industrial side of selection and development of drugs, the primary audience is geared towards the pharmaceutical industry but can also offer valuable information to clinicians, compounding pharmacists, and similarly pharmacy students. Dermal Drug Selection and Development covers the scientific gaps that exist in terms of dermal pharmacokinetics and the resulting uncertainty by clinicians when choosing a drug candidate.
000797983 588__ $$aDescription based on print version record.
000797983 650_0 $$aTransdermal medication.
000797983 7001_ $$aMaibach, Howard I.
000797983 77608 $$iPrint version:$$aTrottet, Lionel$$tDermal Drug Selection and Development : An Industrial Perspective$$dCham : Springer International Publishing,c2017$$z9783319595030
000797983 852__ $$bebk
000797983 85640 $$3SpringerLink$$uhttps://univsouthin.idm.oclc.org/login?url=http://link.springer.com/10.1007/978-3-319-59504-7$$zOnline Access$$91397441.1
000797983 909CO $$ooai:library.usi.edu:797983$$pGLOBAL_SET
000797983 980__ $$aEBOOK
000797983 980__ $$aBIB
000797983 982__ $$aEbook
000797983 983__ $$aOnline
000797983 994__ $$a92$$bISE